Skip to main content
SpringerLink
Log in

Current concepts and future directions in the battle against obesity

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Obesity is a significant unsolved public health problem. Future treatments of obesity will involve application of neuroendocrine concepts that are reviewed in this paper.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neary NM, Small CJ, Bloom SR. Gut and mind. Gut. 2003; 52:918–21.

    Article  PubMed  CAS  Google Scholar 

  2. Allison DB, Fontaine KR, Manson JE, Stevens J, Van Itallie TB. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–8.

    Article  PubMed  CAS  Google Scholar 

  3. Pi-Sunyer FX. The obesity epidemic: Pathophysiology and consequences of obesity. Obesity Research. 2002;10(Suppl2): 97S-104S.

    PubMed  Google Scholar 

  4. Zimmerman RL. The obesity epidemic in America. Clin Fam Prac. 2002;4:229.

    Article  Google Scholar 

  5. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941–8.

    Article  PubMed  CAS  Google Scholar 

  6. Colditz GA. Economic costs of obesity and inactivity. Med Sci Sports Exerc. 1999;31:S663–7.

    Article  PubMed  CAS  Google Scholar 

  7. Labib M. The investigation and management of obesity. J Clin Pathol. 2003;56:17–25.

    Article  PubMed  CAS  Google Scholar 

  8. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: A Life-Table analysis. Ann Intern Med. 2003;138:24–32.

    PubMed  Google Scholar 

  9. Greenway F. Clinical evaluation of the obese patient. Primary Care: Clin Off Prac. 2003;30:341–56.

    Article  Google Scholar 

  10. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115:37S-47S.

    Article  PubMed  CAS  Google Scholar 

  11. Muldoon MF, Mackey RH, Williams KV, et al. Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metabol. 2004;89:266–71.

    Article  CAS  Google Scholar 

  12. Smolar EN. The insulin resistance syndrome. Comp Ther. 1997;23:237–43.

    CAS  Google Scholar 

  13. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278–301.

    Article  PubMed  CAS  Google Scholar 

  14. El-Atat F, Aneja A, McFarlane S, Sowers J. Obesity and hypertension. Endocrinol Metabol Clin. 2003;32:823–54.

    Article  CAS  Google Scholar 

  15. Scott CL. Diagnosis prevention, and intervention for the metabolic syndrome. Am J Cardiol. 2003;92(1A)35i-42i.

    Article  PubMed  Google Scholar 

  16. Korner J, Leibel RL. To eat or not to eat-How the gut talks to the brain. N Engl J Med. 2003;349:926–8.

    Article  PubMed  CAS  Google Scholar 

  17. Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, et al. The catabolic action of insulin in the brain is mediated by melanocortins. J Neurosci. 2002;22:9048–52.

    PubMed  CAS  Google Scholar 

  18. Lustig, RH. The neuroendocrinology of childhood obesity. Pediatr Clin North Am. 2001;48:909–30.

    Article  PubMed  CAS  Google Scholar 

  19. Mudaliar S, Edelman S. Insulin therapy in Type 2 diabetes. Endocrinol Metabol Clin. 2001;30:935–82.

    Article  CAS  Google Scholar 

  20. Neary NM, Goldstone AP, Bloom SR. Appetile regulation: From the gut to the hypothalamus. Clin Endocrinol. 2004;60: 153–60.

    Article  Google Scholar 

  21. Montague CT, Farooqi I, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387:903–8.

    Article  PubMed  CAS  Google Scholar 

  22. Mantzoros CS. The tole of leptin in human obesity and fisease: A review of current evidence. Ann Intern Med. 1999; 130:671–80.

    PubMed  CAS  Google Scholar 

  23. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin voncentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–5.

    Article  PubMed  CAS  Google Scholar 

  24. Van Dielen, FMH, van't Veer C, Buurman WA, Greve JW. Leptin and doluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metabol. 2002; 87:1708–16.

    Article  Google Scholar 

  25. Farooqi SI, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093–103.

    Article  PubMed  CAS  Google Scholar 

  26. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metabol Clin. 2003;32:1005–24.

    Article  CAS  Google Scholar 

  27. Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50: 707–9.

    Article  PubMed  Google Scholar 

  28. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JPH. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metabol. 2002;87:2984–7.

    Article  CAS  Google Scholar 

  29. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 2003;52:947–52.

    Article  PubMed  CAS  Google Scholar 

  30. Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol. 2004;286:G183-G188.

    Article  PubMed  CAS  Google Scholar 

  31. Sturm K, MacIntosh CG, Parker BA, et al. Appetite, food intake, and plasma concentrations of cholecystokinin, ghrelin, and other gastrointestinal hormones in undernourished older women and well-nourished young and older women. J Clin Endocrinol Metabol. 2003;88:3747–55.

    Article  CAS  Google Scholar 

  32. Macintosh CG, Morley JE, Wishart J et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: Evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metabol. 2001;86:5830–7.

    Article  CAS  Google Scholar 

  33. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes. 2003;52:252–9.

    Article  PubMed  CAS  Google Scholar 

  34. Satoh F, Beak SA, Small CJ, et al. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointer-mediate lobe: Lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology. 2000;141:1301–9.

    Article  PubMed  CAS  Google Scholar 

  35. Albu J, Raja-Khan N. The management of the obese diabetic patient. Primary Care; Clin Off Pract. 2003;30:465–91.

    Article  Google Scholar 

  36. Näslund E, King N, Mansten S, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutrit. 2004;91:439–46.

    Article  CAS  Google Scholar 

  37. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001;25:781–92.

    Article  PubMed  CAS  Google Scholar 

  38. Wilding JPH. Neuropeptides and appetite control. Diabet Med. 2002;19:619–27.

    Article  PubMed  CAS  Google Scholar 

  39. Escobar CM, Krajewski SJ, Sandoval-Guzman T, Voytko ML, Rance NE. Neuropeptide Y gene expression is increased in the hypothalamus of older women. J Clin Endocrinol Metabol. 2004;89:2338–43.

    Article  CAS  Google Scholar 

  40. Fehm HL, Smolnik R, Kern W, et al. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4–10) decreases body fat in humans. J Clin Endocrinol Metabol. 2001;86:1144–8.

    Article  CAS  Google Scholar 

  41. Ebihara K, Ogawa Y, Katsuura G, et al. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes. 1999;48:2028–33.

    Article  PubMed  CAS  Google Scholar 

  42. Yang YK, Harmon CM. Recent developments in our understanding of melanocortin system in the regulation of food intake. Obesity Rev. 2003;4:239–48.

    Article  CAS  Google Scholar 

  43. Krude H, Biebermann H, Schnabel D, et al. Obesity due to proopiomelanocortin Deficiency: Three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metabol. 2003;88:4633–40.

    Article  CAS  Google Scholar 

  44. Vaisse C, Clement K, Durand E, et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106:253–62.

    Article  PubMed  CAS  Google Scholar 

  45. Dubern B, Clement K, Pelloux V, et al. Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. J Pediatr. 2001;139:177–81.

    Article  Google Scholar 

  46. Bickerdike MJ, Vickers SP, Dourish CT. 5-HT2C receptor modulation and the treatment of obesity. Diabet Obesity Metabol. 1999;1:207–14.

    Article  CAS  Google Scholar 

  47. Lavianno A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: Clinical implications, pathogenesis and therapeutic strategies. Lancet Oncol. 2003;4:686–94.

    Article  CAS  Google Scholar 

  48. Ryan DH. Use of sibutramine to treat obesity. Primary Care; Clin Off Pract. 2003;30:405–26.

    Article  Google Scholar 

  49. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–8.

    Article  PubMed  CAS  Google Scholar 

  50. Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metabol Clin. 2003;32:895–914.

    Article  CAS  Google Scholar 

  51. Burger AJ, Charlamb MJ, Singh S, et al. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol. 2001;79(2–3):159–65.

    Article  PubMed  CAS  Google Scholar 

  52. Rossi M, Kim MS, Morgan DGA, et al. A C-terminal fragment of agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology. 1998;139:4428–31.

    Article  PubMed  CAS  Google Scholar 

  53. Katsuki A, Sumida Y, Gabazza EC, et al. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metabol. 2001;86:1921–4.

    Article  CAS  Google Scholar 

  54. Shen CP, Wu KK, Shearman LP, et al. Plasma agouti-related protein level: A possible correlation with fasted and fed states in humans and rats. J Neuroendocrinol. 2002;14:607–10.

    Article  PubMed  CAS  Google Scholar 

  55. Pi-Sunyer F-X, Laferrere B, Aronne LJ, Bray GA. Therapeutic controversy: Obesity-A modern day epidemic. J Clin Endocrinol Metabol. 1999;84:3–12.

    Article  CAS  Google Scholar 

  56. Weigle DS. Pharmacological therapy of obesity: Past, present and future. J Clin Endocrinol Metabol. 2003;88:2462–9.

    Article  CAS  Google Scholar 

  57. Marks DL, Boucher N, Lanouette CM, et al. Ala67Thr polymorphism in the agouti-related peptide gene is associated with inherited leanness in humans. Am J Med Gen. 2004; 126A:267–71.

    Article  Google Scholar 

  58. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology. 1993;133:1753–8.

    Article  PubMed  CAS  Google Scholar 

  59. Gay C, Shane-McWhorter L, Williams K, Stone MB. Physician prescribing of anorexigenics for weight loss in Salt Lake County, Utah. Pharmacotherapy. 2000;20:967–3.

    Article  PubMed  CAS  Google Scholar 

  60. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–7.

    Article  PubMed  CAS  Google Scholar 

  61. Brolin RE Gastric bypass. Surg Clin N Am. 2001;81:1077–95.

    Article  PubMed  CAS  Google Scholar 

  62. Cummings DE. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.

    Article  PubMed  Google Scholar 

  63. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26:2370–7.

    Article  PubMed  CAS  Google Scholar 

  64. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatr. 2003;160:255–61.

    Article  PubMed  Google Scholar 

  65. Brown RO, Orr CD, Hanna DL, Williams JE, Dickerson RN. Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy. 2002;22:831–5.

    Article  PubMed  CAS  Google Scholar 

  66. Anthanelli RM, Despres J-P. Conference Rapid News Summaries. Effects of Rimonabant in the Reduction of Major Cardiovascular Risk Factors. Results From the STRATUSUS Trial (Smoking Cessation in Smokers Motivated to Quit and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in Overweight/Obese Patients with Dyslipidemia). Annual Scientific Session 2004 Online-Conference Rapid News Summaries. March 9, 2004. Annual Scientific Session 2004 Online. Accessed April 23, 2004. http://www. acc04online.org/daily/news/newssummary.asp?sid=1&stid=14&news1d=2004-03-.0.9

  67. Rimonabant-selective CB1 Endocannabinoid receptor antagonist for the treatment of obesity. The Website for Drug Development Industry. Sanofi-Synthelabo. Accessed June 10, 2004. http://www.drugdevelopment-technology.com/ projects/rimonabant/.

  68. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569–74.

    Article  PubMed  CAS  Google Scholar 

  69. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, Fla

    Aneesa Niravel BS (Medical Student) & Edward N. Smolar MD (Clinical Assistant Professor of Medicine)

Authors
  1. Aneesa Niravel BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward N. Smolar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. In addition, the authors discuss the use of an investigative product known as Exenatide.

About this article

Cite this article

Niravel, A., Smolar, E.N. Current concepts and future directions in the battle against obesity. Compr Ther 30, 164–172 (2004). https://doi.org/10.1007/s12019-004-0014-2

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-004-0014-2

Keywords

Search

Navigation